(RTTNews) - Can-Fite BioPharma Ltd. (CANF) reported first-half 2026 financial results and clinical updates, highlighting longer-than-anticipated overall survival in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC).